Eric Lefkofsky and his company, Tempus, are looking to personalize health care through the use of machine learning and AI technologies that rely on data. By gathering data, physicians will be able to better deal with the cancer that is plaguing patients by learning from what has worked and what hasn’t. Tempus is able to help physicians by sequencing DNA/RNA and looks to gather molecular data in one place so it is easier for cancer patients to be treated in real-time using hard data. The company is already making waves in the industry and has been named a Chicago top ten health tech company. What’s even more interesting is the fact that Tempus may be able to help patients who suffer from Alzheimer’s disease in the future. It is hoped that data gathered from Alzheimer’s patients will be able to help physicians discover the disease in people much sooner than they are able to at the present time.
Eric Lefkofsky is the Chief Executive Officer and co-founder of the tech company, Tempus, which is working to battle cancer through an operating system that draws on the data of past patients. He is also a philanthropist who co-created the Lefkofsky Family Foundation, which is a private charity organization that works to enhance people’s lives in numerous ways. He is also a Trustee of The Museum of Science and Industry and World Business Chicago, Lurie Children’s Hospital of Chicago, and The Art Institute of Chicago and works with a spread of charitable organizations who advance initiatives related to the arts and culture, medicine, and basic human rights.
Eric Lefkofsky is also a founding partner of Lightbank, which is a venture fund that invests in technologies that aim to shake up their respective industries. Along these lines, he wrote a book named Accelerated Disruption that explains how to build companies that disrupt entire industries. Lefkofsky has always been a supporter of education and works as an adjunct professor with the University of Chicago. He received his Juris Doctor while studying at the University of Michigan Law School after graduating from the University of Michigan.
Learn More: lefkofskyfoundation.com/about-eric-lefkofsky/
Clay Siegall endeavors to enhance the lives of cancer patients through biomedicine. He uses research and innovation to develop solutions for the patients and reduce their suffering. Siegall has 15 patents and has published several research findings and over 70 related articles.
Dr. Siegall supports legislations that help make the process of developing patient therapists efficient. Current therapies are not as effective as there are possibilities of relapse. He is encouraged by the nation’s efforts in prioritizing funding for biomedical research and approves of the current FDA model.
Dr. Clay Siegall is the Chairman, President, co-founder, and CEO, of Seattle Genetics. His leadership oversaw the creation of antibody cancer therapies such as ADCETRIS. He has also been on the fore front raising capital for the company and has since raised over 1.2 billion dollars through public-private partnerships and IPOs. Before Seattle Genetics, he worked with the National Cancer Institute, the National Institutes of Health, and Bristol-Myers Squibb Pharmaceutical Research Institute.
Seattle Genetics came into the market in 1998, when distinguishing chemotherapy meant for cancer cells and that for normal cells was a daunting task. The objective of the of the company was to improve the lives of people battling cancer through initiating better therapies that cater for current unmet needs. In depth research and pharmaceutical development, innovation, and passion helped transform Seattle into a top company in the antibody-drug conjugates sector. ADCTERIS is now globally used. The company has also acquired strategic licenses for the ADC technology with global medical manufacturing and distribution companies such as GlaxoSmithKline and has generated over 350 million dollars. 20 or more ADCs are now using their technology for clinical development.
Currently, Seattle Genetics is working on changing the existing treatment plan for Hodgkin Lymphoma by using ADCs with existing chemotherapies. They have been improving Adcetris to replace Bleomycin to treat the disease. According to the Investments Business daily, the Echelon-1 is set to increase Seattle Genetic’s value.
Clay sits on the Alder Bio Pharmaceuticals Board of Directors. He holds a Generics P.H.D and B.S in Zoology from George Washington University and the University of Maryland. The University of Maryland recognized Dr. Siegall as the alumnus of the year 2013 in Computer, Natural Science, and Math. Ernst &Young recognized him as the Pacific Northwest entrepreneur of 2012.